Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Unknown 3Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Esophageal Neoplasms 9Advanced Gastric Cancer 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Liver Neoplasms 5Glioma 5Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Carboplatin 71Paclitaxel 49Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 39Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8capmatinib 7Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6Mastectomy, Segmental 6ceritinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × apatinib × Clear all
NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Hunan Cancer Hospital

Phase 2 Unknown
63 enrolled
Thoracic

Adenocarcinoma of Lung

NCT03376737 2017-12-18

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Thoracic

Adenocarcinoma of Lung

NCT02691871 2016-02-25

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Unknown
20 enrolled
Thoracic

Adenocarcinoma of Lung

NCT02493582 2016-02-05

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

The First People's Hospital of Changzhou

Phase 2 Active not recruiting
400 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡